Glaukos Corp GKOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
-
Glaukos Announces Participation in Wells Fargo Healthcare Conference
-
Glaukos Announces Second Quarter 2026 Financial Results
-
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt
-
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
-
Glaukos Shares Rise After FDA Approves NDA Supplement for iDose TR
Trading Information
- Previous Close Price
- $163.17
- Day Range
- $163.01–168.08
- 52-Week Range
- $73.16–191.62
- Bid/Ask
- $136.78 / $189.00
- Shares Outstanding
- 58.98M
- Market Cap
- $9.66B
- Volume/Avg
- 742,802 / 797,102
Key Statistics
- Price/Earnings (Normalized)
- 119.35
- Price/Sales
- 15.43
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,094
- Website
- https://www.glaukos.com
Valuation
|
Metric
|
GKOS
|
|---|---|
Price/Earnings (Normalized) | 119.35 |
Price/Book Value | 14.07 |
Price/Sales | 15.43 |
Price/Cash Flow | 182.28 |
Price/Earnings
GKOS
Financial Strength
|
Metric
|
GKOS
|
|---|---|
Quick Ratio | 4.15 |
Current Ratio | 5.04 |
Interest Coverage | −40.31 |
Quick Ratio
GKOS
Profitability
|
Metric
|
GKOS
|
|---|---|
Return on Assets (Normalized) | −4.72% |
Return on Equity (Normalized) | −6.24% |
Return on Invested Capital (Normalized) | −6.03% |
Return on Assets
GKOS
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|l^&Y$@ | LOCK|@m&@Y | $167B | |||
| Medtronic PLC
MDT
| LOCK|$fgGF^ | LOCK|#MkTX | $111B | |||
| Stryker Corp
SYK
| LOCK|@^W$j$!@ | LOCK|sXN | $105B | |||
| Boston Scientific Corp
BSX
| LOCK|gv&#%C | LOCK|NkVr | $63B | |||
| Edwards Lifesciences Corp
EW
| LOCK|w?%FM^V | LOCK|Y$nq | $49B | |||
| DexCom Inc
DXCM
| LOCK|ZJpP%^ZL | LOCK|V<vX& | $33B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|czPq&?< | LOCK|<y< | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|?B# | LOCK|@M | $23B | |||
| Steris PLC
STE
| LOCK|?%T?f>X | LOCK|%CVW^ | $20B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|?lQ%g&Rd | LOCK|C& | $17B |
United States